I'm still amazed by the accelerating pace of new modality drugs gaining approval. We've updated the chart from last year and are making it available for download and use in slides. [withdrawn drugs not shown, and yes, next solve access]. BioCentury. biocentury.com/article/644637

Strongly recommended review by the Engelhardt group on cardiovascular miRNA therapeutics also highlighting the leading position of #CDR132L by Cardior Pharmaceuticals in the clinical development for patients with #heartfailure. ncbi.nlm.nih.gov/pmc/articles/P…

MicroRNAs as therapeutic targets in cardiovascular disease, all you want and have to know, review by Stefan Engelhardt, TU Munich and Munich Hospital right of river #isar ncbi.nlm.nih.gov/pmc/articles/P…

#DYK that the majority of the human genome is transcribed into ncRNAs that regulate cellular processes? Cardior is utilizing #ncRNAs to modulate #miRNAs and #lncRNAs, potentially reversing the pathology of heart diseases. Find out more: bit.ly/3AtiTUE #CardiorFacts

For our 3rd #CardiorFacts post, we dive into specific microRNAs linked to #cardiacdiseases. Cardior’s lead ncRNA candidate targets miRNA-132, a central regulator of pathological cardiac remodeling. Read more here: bit.ly/3chTnIB

From tomorrow onwards Cardior’s CSO @ThomasThum_Lab & CMO Rahul Agrawal as well as Head of Competitive Intelligence Sandor Batkai will be at the European Society for Cardiology Congress 2022 in Barcelona. Access full details on their presentations here: bit.ly/3PYgfe9

Congratulations to our colleagues Barbara (Head of IP) and Peter (VP, BD & Licensing) on their #promotions! Barbara and Peter continue to play an instrumental role in advancing a novel class of cardiac therapeutics and we are happy to have them on the Cardior team.

Today we announced the CE marking of our proprietary CardiorHealth miR-132 PCR kit used in our ongoing Phase 2 HF-REVERT study. It ensures consistent measurement of circulating microRNA-132 levels following treatment with our lead candidate, CDR132L: cardior.de/wp-content/upl…

Cardior welcomes two new Board members, luc debruyne from Fund+ & Christoph Broja from EQT Group LifeSciences. They will replace Jan vd Bossche and Karin Kleinhans, whom we thank for their contributions to our mission of becoming the leader in ncRNA-based therapies for #cardiacdiseases

We’re travelling back from #Munich full of excitement as we received the Pharma Trend DE Innovation Award for our lead candidate CDR132L as the Most Innovative Product in 2022! We are grateful for this recognition for CDR132L as a potential game changer in treating cardiac diseases

In patients with new-onset or worsening heart failure, albuminuria is consistently associated with clinical, echocardiographic, and circulating biomarkers of congestion. #EHJ ow.ly/UQeY50KRgv9

Donnerstag morgen 8.00 geht es bei den #DGKHerztage gleich los mit der Session zum Interdisziplinären #Herzinsuffizienz Management‼️ ⁦Deutsche Gesellschaft für Kardiologie⁩ ⁦Young DGK⁩ ⁦Peter Lüdike⁩ ⁦Djawid Hashemi⁩ ⁦Maria Papathanasiou⁩ ⁦Daniel Messiha, MD⁩ ⁦Tienush Rassaf⁩ ⁦

#WorldHeartDay 2022

Today’s World Heart Day organized by the WORLD Heart Federation is a cause close to our ❤️ and an opportunity for everyone to consider how we can beat heart diseases by focusing on global access to healthcare, a clean environment and healthy minds.More at bit.ly/3PoVMyA

Today’s #CardiorFacts highlights a review focused on non-coding RNA (ncRNA) biology & describes the critical functional roles that ncRNAs play in heart disease pathogenesis. Learn more about these unique therapeutic targets here: pubmed.ncbi.nlm.nih.gov/27535639/

Cardior CSO @ThomasThum_Lab is presenting today at the #RNA Leaders USA Congress by LSX Leaders on how non-coding RNA-based therapeutics can trigger a paradigm shift in treating heart diseases. For more info visit: lsxleaders.com/rna-leaders-us…

Today we announced the appointment of Axel-Sven Malkomes as Cardior’s CFO. He joins us at a crucial time as we continue to expand our clinical and operational footprint globally, with a focus on the US. Welcome to the team Axel-Sven! cardior.de/wp-content/upl…

We are celebrating American #HeartMonth to raise awareness for #HeartDiseases, the leading cause of death in the US. Learn more about how to keep your ❤️ healthy at NIH’s site bit.ly/3JiJRTC & how we aim to address the root causes of ❤️ diseases cardior.com

Another successful #DGKJahrestagung Strong showing from the Thum Lab w/ 16 posters & talks including a poster award nomination from Anita! honored to have the success of Cardior Pharmaceuticals - a Novo Nordisk company featured in the opening ceremony, session of the congress president and highlight session

We are very happy to have Leon Carayannopoulos on the Board! Leon's experience in translational development, clinical pharmacology and early patient programs will be a valuable contribution to Cardior Pharmaceuticals - a Novo Nordisk company as we continue our #HFREVERT Phase 2 study evaluating #CDR132L.